Gilead Sciences was founded in 1987 and is headquartered in Foster City, US

Report incorrect company information

CEO

COO

Report incorrect company information

Gilead Sciences has offices in Foster City, Fremont, Oceanside, San Dimas and in 2 other locations

Foster City, US (HQ)

333 Lakeside Dr

Branford, US

36 E Industrial Rd

Fremont, US

7601 Dumbarton Cir

Oceanside, US

4049 Avenida De La Plata

San Dimas, US

650 Cliffside Dr

Seattle, US

199 E Blaine St

Report incorrect company information

Gilead Sciences's revenue was reported to be $26.11 b in FY, 2017

USD | |
---|---|

## Revenue (FY, 2017) | 26.1 b |

## Gross profit (FY, 2017) | 21.7 b |

## Gross profit margin (FY, 2017), % | 83.3% |

## Net income (FY, 2017) | 4.6 b |

## EBIT (FY, 2017) | 14.1 b |

## Market capitalization (18-Apr-2018) | 99.8 b |

## Cash (31-Dec-2017) | 7.6 b |

## EV | 123 b |

Gilead Sciences's current market capitalization is $99.8 b.

- Source: SEC Filings

Annual

Quarterly

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 2.8 b | 5 b | 6.5 b | 6 b | 7.6 b | 8.2 b | 8.3 b | 7.8 b | 7.8 b | 7.5 b | 6.5 b | 7.1 b |

## Cost of goods sold | 681.9 m | 813.2 m | 924.7 m | 987.3 m | 882 m | 998 m | 1.1 b | 1.2 b | 864 m | 1.1 b | 957 m | 1.1 b |

## Gross profit | 2.1 b | 4.2 b | 5.6 b | 5.1 b | 6.7 b | 7.2 b | 7.2 b | 6.6 b | 6.9 b | 6.4 b | 5.5 b | 6 b |

| 75% | 84% | 86% | 84% | 88% | 88% | 87% | 85% | 89% | 85% | 85% | 84% |

- Source: SEC Filings

Annual

Quarterly

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Cash | 2 b | 6.4 b | 8.7 b | 6.2 b | 10.6 b | 7.4 b | 14 b | 6.3 b | 6.5 b | 9.8 b | 10.3 b | 8.7 b |

## Accounts Receivable | 2 b | 3.2 b | 3.4 b | 2.9 b | 4.8 b | 5.3 b | 6.1 b | |||||

## Inventories | 1.9 b | 2.1 b | 2.1 b | 1.9 b | 1.9 b | 2 b | 2 b | 1.9 b | 1.9 b | 1.9 b | 1.5 b | 1.4 b |

## Current Assets | 7 b | 13 b | 15.5 b | 12.6 b | 20.1 b | 18.1 b | 25.9 b | 19.3 b | 18.4 b | 21.4 b | 21.4 b | 28.6 b |

Annual

Quarterly

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Net Income | 785.2 m | 2.2 b | 3.7 b | 2.7 b | 4.3 b | 8.8 b | 13.4 b | 3.6 b | 7.1 b | 10.4 b | 2.7 b | 5.8 b |

## Depreciation and Amortization | 75 m | 116 m | 42 m | 85 m | 129 m | 49 m | 103 m | |||||

## Inventories | (634 m) | (659 m) | (14 m) | (97 m) | (274 m) | (5 m) | (14 m) | |||||

## Accounts Payable | 620 m | 288 m | (239 m) | (67 m) | (115 m) | (262 m) | (399 m) |

USD | Y, 2017 |
---|---|

## EV/EBIT | 8.7 x |

## EV/CFO | 10.3 x |

## EV/FCF | 10.9 x |

## Revenue/Employee | 2.9 m |

## Financial Leverage | 3.4 x |

FY, 2016 | |
---|---|

## Countries | 30 |

## Phase I Trials Products | 3 |

## Phase II Trials Products | 12 |

## Phase III Trials Products | 6 |

Acquired Company | Date | Deal Size |
---|---|---|

Kite Pharma | August 28, 2017 | $11.90 b |

Report incorrect company information